Replies to post #243346 on Avid Bioservices Inc (CDMO)

[asmarterwookie]

Thanks nuke...had to get my goldrush on....afterall if this golden goose lays a lead egg I need to know how to mine the gold! LOL!!!

My eyes crossed starting to read that paper and I want to read it again when I am rested....

You said two fold...looks like the MOA may squeak a couple more folds in there...or was that me seeing double as my eyes crossed??

Thanks again, I want to have good eyes as I have to re-google terms to remember what the heck I am reading...as you probably know by my writings...I am a get the gist of it kinda guy...this paper is pure brilliant scientific writing in the deepest context of cellular biology. It will take a couple hours to try and understand that flow.

Goodnight and thanks again for continuing the PS Targeting / APP MOA conversation going!!


wook

[north40000]

I 2nd wook's thank you --- you, and now many others, remind me of the facile research and analysis FTM brought to the PPHM board.

[asmarterwookie]

Bavituximab, the lead compound in Peregrine's immuno-oncology development program, blocks PS to remove this immunosuppressive signal and sends an alternate immune activating signal. PS targeting antibodies have been shown to shift the functions of immune cells in tumors, resulting in robust anti-tumor immune responses.

So we all can agree that Peregrines' PS Licensed Technology is two fold in the broadest of context...The PATENTED IP is the targeting of PS...while the Anti-Phosphatidylserine Platform(APP) is being built up that IP.

I find the qoute "resulting in ROBUST anti-tumor immune response" very interesting. Is it robust alone or in combination?

Have tighter controls on who is conducting and viewing trials shown a more robust response? What about the latency?

Time will tell what this technology can REALLY do!

Enjoy the Day!

wook